Author:
Overgaard Silja H.,Sørensen Signe B.,Munk Heidi L.,Nexøe Anders B.,Glerup Henning,Henriksen Rikke H.,Guldmann Tanja,Pedersen Natalia,Saboori Sanaz,Hvid Lone,Dahlerup Jens F.,Hvas Christian L.,Jawhara Mohamad,Andersen Karina W.,Pedersen Andreas K.,Nielsen Ole H.,Bergenheim Fredrik,Brodersen Jacob B.,Heitmann Berit L.,Halldorsson Thorhallur I.,Holmskov Uffe,Bygum Anette,Christensen Robin,Kjeldsen Jens,Ellingsen Torkell,Andersen Vibeke
Abstract
BackgroundBiologic disease-modifying drugs have revolutionised the treatment of a number of chronic inflammatory diseases (CID). However, up to 60% of the patients do not have a sufficient response to treatment and there is a need for optimization of treatment strategies.ObjectiveTo investigate if the treatment outcome of biological therapy is associated with the habitual dietary intake of fibre and red/processed meat in patients with a CID.MethodsIn this multicentre prospective cohort study, we consecutively enrolled 233 adult patients with a diagnosis of Crohn's Disease, Ulcerative Colitis, Rheumatoid Arthritis (RA), Axial Spondyloarthritis, Psoriatic Arthritis and Psoriasis, for whom biologic therapy was planned, over a 3 year period. Patients with completed baseline food frequency questionnaires were stratified into a high fibre/low red and processed meat exposed group (HFLM) and an unexposed group (low fibre/high red and processed meat intake = LFHM). The primary outcome was the proportion of patients with a clinical response to biologic therapy after 14–16 weeks of treatment.ResultsOf the 193 patients included in our primary analysis, 114 (59%) had a clinical response to biologic therapy. In the HFLM group (N = 64), 41 (64%) patients responded to treatment compared to 73 (56%) in the LFHM group (N = 129), but the difference was not statistically significant (OR: 1.48, 0.72–3.05). For RA patients however, HFLM diet was associated with a more likely clinical response (82% vs. 35%; OR: 9.84, 1.35–71.56).ConclusionHabitual HFLM intake did not affect the clinical response to biological treatment across CIDs. HFLM diet in RA patients might be associated with better odds for responding to biological treatment, but this would need confirmation in a randomised trial.Trial registration(clinicaltrials.gov), identifier [NCT03173144].
Funder
Horizon 2020
Oak Foundation
Knud og Edith Eriksens Mindefond
Subject
Nutrition and Dietetics,Endocrinology, Diabetes and Metabolism,Food Science
Cited by
6 articles.
订阅此论文施引文献
订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献